A-A+
A-A+

Overview of Pre-Market Approval Framework for Novel Food

Novel food comprises food or food ingredients that do not have a history of use as food over the past 20 years. Examples of novel food include cultivated meats and alternative proteins produced using precision fermentation.

 

Contents in this page

      Why is there a pre-market approval framework for novel food?

      Demand for novel food has been increasing due to growing consumer interest in healthier, more sustainable, and innovative food options.

      The FSSA provides a framework for evaluating novel food to ensure consumers here are protected while fostering food innovation. The evaluation is to lead to a pre-market approval to supply novel food in Singapore.

      Food safety remains a top priority in Singapore. All novel food intended for supply in Singapore will be rigorously assessed before pre-market approval may be granted for its supply in Singapore.

      Who must obtain pre-market approval of novel food?

      Anyone who wants to farm, manufacture, distribute or sell novel food in Singapore must ensure that the novel food has pre-market approval. 

      From 28 November 2025, Parts 5 and 8 FSSA make it an offence to supply in Singapore any defined food, to handle food intended for supply in a way that will or is likely to make the food a defined food, or to produce primary produce that is a defined food.


      What is the pre-market approval framework for novel food?

      The framework comprises a set of rules and guidelines to ensure the safety of novel food manufactured, imported, distributed, and sold in Singapore.

      icon-accordion-down

      Novel food may refer to the following:

      • A substance (which may consist of, be isolated from or produced from, cell culture or tissue culture derived from animals, plants, bacteria or yeast, fungi, algae or other micro-organism) that has not been used to a significant degree as food for a period of at least 20 years, whether within or outside Singapore;
      • A food that has been manufactured, prepared or preserved by a process that has not been previously used in food production for a period of at least 20 years, whether within or outside Singapore;
      • A food consisting of, isolated from or produced from material of mineral origin that has not been previously used in food production for a period of at least 20 years, whether within or outside Singapore; or
      • A food that contains or consists of engineered nanomaterials.
      icon-accordion-down

      An applicant for pre-market approval for a novel food must provide safety assessments of the novel food that identify risks and ensure these risks are appropriately managed, accompanied by scientific evidence demonstrating that the novel food as a food or an ingredient in food does not pose a risk to human health.

      Details of what is required in an application for pre-market approval can be found in the Second Schedule to the Food Safety and Security (FSSA Authorisations — Administration) Regulations 2025.


      icon-accordion-down

      A novel food must be covered by pre-market approval from SFA before it can be lawfully supplied in Singapore, or handled (like manufacturing) for supply here, or reared or cultivated here. 

      A pre-market approval for a novel food is not perpetual and may be cancelled by SFA under certain conditions set out in section 112 FSSA. 

      (a) the pre‑market approval had been obtained by fraud or misrepresentation;

      (b) any condition of the pre‑market approval is contravened or not complied with;

      (c) after the grant of the pre‑market approval, there has been a material change to —

      (i) the method by which the novel food or genetically modified food is manufactured, prepared, preserved, packaged or stored; or

      (ii) any other information relating to the novel food or genetically modified food which was provided in connection with the application for the pre-market approval; or

      (d) the public interest of Singapore requires the cancellation of the pre‑market approval.

      The pre-market approval for a novel food also ends when the food ceases to be a novel food.

      Refer to the list of approved novel foods in Singapore

      SFA Novel Food Safety Expert Working Group

      To ensure rigorous review of safety assessments, SFA established the “SFA Novel Food Safety Expert Working Group” to provide scientific advice. The expert working group comprises 13 experts with diverse expertise across relevant disciplines. More information about the members can be found below.

       Members of the Novel Food Safety Expert Working Group:

      Chair  
      Professor John Lim
      Executive Director, Centre of Regulatory Excellence, Duke-NUS Medical School
      Core Lead (Policy), SingHealth Duke-NUS Global Health Institute Senior Advisor, Ministry of Health, Singapore
      Chairman, Consortium for Clinical Research & Innovation, Singapore
      Members DesignationSpecialisation field(s) 
      Professor Zhou WeibiaoHead of Department, Food Science and Technology, National University of SingaporeFood science (Food engineering, food processing and functional food)
      Professor William ChenDirector, Food Science and Technology Programme, Nanyang Technological UniversityFood science (fermentation)
      Professor Christiani Jeyakumar HenrySenior Advisor, Singapore Institute of Food and Biotechnology Innovation, A*STARNutrition
      Adjunct Professor Sebastian Maurer- StrohExecutive Director, Bioinformatics Institute, A*STARBioinformatics (allergenicity prediction)
      Adjunct Associate Professor Annie LingGroup Director, Policy, Research and Surveillance Division, Health Promotion BoardEpidemiology
      Adjunct Associate Professor Jeffrey CutterSenior Consultant, Communicable Disease Group, Ministry of HealthPublic health
      Associate Professor Yew Wen ShanHead, Department of Biochemistry, Yong Loo Lin School of Medicine, National University of SingaporePrecision fermentation and microbiology
      Assistant Professor Ching JianhongAssistant Professor, Director, Metabolomics @Duke-NUS Medical SchoolMetabolomics
      Professor Chan Chun Yong, EricProfessor, Department of Pharmacy and Pharmaceutical Sciences, Faculty of Science, National University of Singapore Pharmacology and Toxicology (physiological-based pharmacokinetics-pharmacodynamics modelling)
      Associate Professor Tan Soo YongHead of Advanced Molecular Pathology Laboratory, Institute of Molecular and Cell Biology, A*STARBiobanking, molecular pathology, cancer genomics
      Clinical Associate Professor Chua Mei Chien  Head and Senior Consultant, Department of NeonatologyPaediatrics 
      Associate Professor Linda Zhong LidanDirector, Biomedical Sciences and Chinese Medicine, School of Biological Sciences, Nanyang Technological UniversityBotanicals

       

       

      For more information
      You can contact us via the SFA Online Feedback Form.

      Last updated: 18 Apr 2026